TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23343906

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) 0.1 mg/kg·day with prednisone at 0.5 mg/kg·day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Cyclophosphamide (CTX) 0.5-0.75 g/m(2)·month, i.v. with prednisone at 0.8 mg/kg·day
Number of subjects: 33
Study: 21078629

Group type: EXPERIMENTAL
Intervention: Transdermal 17β-oestradiol (50 µg/day)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 19797249

Group type: EXPERIMENTAL
Intervention: Fentanyl 25 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.3 ml
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sufentanil 5 microg + bupivacaine 0.5% (0.8 ml) + normal saline 0.7 ml
Number of subjects: 70
Study: 17113886

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, 50 mg/24 hr
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 14760143

Group type: EXPERIMENTAL
Intervention: Individualised complete written action plans with 2-4 action points and both inhaled corticosteroids (ICS) and oral corticosteroids (OCS)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Action points based on personal best peak expiratory flow (PEF)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Action points based on percentage predicted PEF
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Incomplete action plans
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Non-specific action plans
Number of subjects: 26
Study: 11313314

Group type: EXPERIMENTAL
Intervention: Peginterferon alpha2a (180 microg once weekly for 48 weeks)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Standard interferon alpha2a (thrice weekly for 48 weeks)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 33
Study: 9150824

Group type: EXPERIMENTAL
Intervention: Exposure alone (E)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Exposure associated with imipramine (EI)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cognitive therapy supplementing exposure (EC)
Number of subjects: 21
Study: 7715641

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 665

Group type: COMPARATOR
Intervention: Low-molecular-weight heparin
Number of subjects: 665
Study: 3056476

Group type: EXPERIMENTAL
Intervention: Hyaluronidase (500 U/kg given every six hours for 48 hours)
Number of subjects: 730

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study: 30570386

Group type: EXPERIMENTAL
Intervention: Mediterranean-style diet (MedDiet) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Social group-program
Number of subjects: 0
Study: 31290948

Group type: EXPERIMENTAL
Intervention: Short-term treatment of internet and computer game addiction (STICA)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Wait-list control (WLC)
Number of subjects: 143
Study: 28532623

Group type: EXPERIMENTAL
Intervention: Standard sequential (SS) treatment: lansoprazole 30mg b.i.d. + amoxicillin 1g b.i.d. for 5 days, followed by lansoprazole 30mg b.i.d., clarithromycin 500mg b.i.d., and metronidazole 500mg t.i.d. for 5 days
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Extended sequential (ES) treatment: same as SS but for 7+7 days
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Extended sequential + bismuth (ES+B) treatment: same as ES but with colloidal bismuth 600mg b.i.d. for 14 days
Number of subjects: 280
Study: 25672574

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily during the first 3 weeks of each 4-week cycle
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Regorafenib
Number of subjects: 32
Study: 23537327

Group type: EXPERIMENTAL
Intervention: Motivational interviewing training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Usual care (non-trained nurses)
Number of subjects: 65
Study: 21729518

Group type: EXPERIMENTAL
Intervention: RoTEM® analysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional coagulation tests
Number of subjects: 60
Study: 18834457

Group type: EXPERIMENTAL
Intervention: Prognostic Index (PI) based on age and mean 24 hours diastolic and systolic blood pressure.
Number of subjects: 105
Study: 17209788

Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD) treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no EMD treatment)
Number of subjects: 30
Study: 15067859

Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted hepatitis B vaccine
Number of subjects: 100

Group type: COMPARATOR
Intervention: Engerix-B (alum-adjuvanted yeast-derived HBV vaccine)
Number of subjects: 100
Study: 10648265

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (206000 IU, 103000 IU if aged <12 mo) every 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9054741

Group type: EXPERIMENTAL
Intervention: Integrilin (highest dose)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 9728228

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) infusion of 1 mg kg‐1 h‐1 during surgery
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no PTX)
Number of subjects: 20
Study: 2888474

Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Atracurium
Number of subjects: 20
Study: 31961904

Group type: EXPERIMENTAL
Intervention: Barbell back squatting
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standing (control)
Number of subjects: 24
Study: 29185133

Group type: EXPERIMENTAL
Intervention: Resistance exercise program (twice a week for 12 weeks)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional drug therapy
Number of subjects: 41
Study: 28901796

Group type: EXPERIMENTAL
Intervention: 5-mg saxagliptin
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240

Group type: COMPARATOR
Intervention: Switching from placebo to saxagliptin
Number of subjects: 240
Study: 26160879

Group type: EXPERIMENTAL
Intervention: pomalidomide + low-dose dexamethasone
Number of subjects: 455

Group type: COMPARATOR
Intervention: high-dose dexamethasone
Number of subjects: 455
Study: 29350176

Group type: EXPERIMENTAL
Intervention: Prototype 4-mg nicotine lozenge
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prototype III 4-mg nicotine lozenge
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: All prototype 4-mg nicotine lozenges
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Prototype 4-mg nicotine lozenges
Number of subjects: 39

Group type: COMPARATOR
Intervention: Reference 4-mg nicotine lozenge
Number of subjects: 39
Study: 21978726

Group type: EXPERIMENTAL
Intervention: 500 mg Ferric Carboxymaltose (FCM) in two doses 5 days apart
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1000 mg Ferric Carboxymaltose (FCM) given on day 28
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Additional 500 mg Ferric Carboxymaltose (FCM) for those not responding to initial treatment
Number of subjects: 46
Study: 18644110

Group type: EXPERIMENTAL
Intervention: Needs-oriented discharge planning and monitoring intervention (NODPAM)
Number of subjects: 490
Study: 16583234

Group type: EXPERIMENTAL
Intervention: Volume-extended training for 6 months
Number of subjects: 12
Study: 12672844

Group type: EXPERIMENTAL
Intervention: Cemented total hip arthroplasty
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty
Number of subjects: 98

Group type: COMPARATOR
Intervention: Unilateral total hip arthroplasty (cementless)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Bilateral total hip arthroplasty (one cemented, one cementless)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cemented group (zirconia head)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Cementless group (cobalt-chromium head)
Number of subjects: 98
Study: 11079086

Group type: EXPERIMENTAL
Intervention: MRI-guided puncture and catheterization of the biliary system
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluoroscopic guidance
Number of subjects: 6
Study: 8730253

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg b.d. for 4 weeks plus amoxycillin 1 g t.d.s. during the last 2 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily for 4 weeks plus classical triple therapy (tripotassium dicitratobismuthate 240 mg b.d., amoxycillin 1 g t.d.s. and tinidazole 500 mg b.d.) for the last 2 weeks
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 96
Study: 1475266

Group type: EXPERIMENTAL
Intervention: Pall PF 30 filter
Number of subjects: 92

Group type: COMPARATOR
Intervention: No filter (control)
Number of subjects: 92
Study: 6326788

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Tubocurarine
Number of subjects: 40
Study: 30067139

Group type: EXPERIMENTAL
Intervention: Dorsiflexion exercise
Number of subjects: 36

Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 36
Study: 29084737

Group type: EXPERIMENTAL
Intervention: More intensive antiplatelet therapy (vorapaxar and ticagrelor pooled)
Number of subjects: 47611

Group type: COMPARATOR
Intervention: Background antiplatelet therapy (aspirin monotherapy)
Number of subjects: 47611
Study: 27401475

Group type: EXPERIMENTAL
Intervention: WelTel SMS intervention (interactive weekly SMS 'How are you?')
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: WelTel SMS intervention
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 600
Study: 24527503

Group type: EXPERIMENTAL
Intervention: 2 sessions of real rTMS (10 Hz, 110% of motor threshold)
Number of subjects: 108

Group type: COMPARATOR
Intervention: 2 sessions of sham rTMS
Number of subjects: 108
Study: 22648287

Group type: EXPERIMENTAL
Intervention: Therapeutic cervical facet joint injections at bilateral C5/C6 and C6/C7
Number of subjects: 400

Group type: COMPARATOR
Intervention: Non-injection group (group N)
Number of subjects: 400
Study: 20543705

Group type: EXPERIMENTAL
Intervention: DAILIES AquaComfort Plus for daily disposable, daily wear
Number of subjects: 83
Study: 17010102

Group type: EXPERIMENTAL
Intervention: 120 mg G. biloba + 100 mg cilostazol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 120 mg G. biloba + 75 mg clopidogrel
Number of subjects: 10

Group type: COMPARATOR
Intervention: cilostazol
Number of subjects: 10

Group type: COMPARATOR
Intervention: G. biloba
Number of subjects: 10

Group type: COMPARATOR
Intervention: clopidogrel
Number of subjects: 10

Group type: COMPARATOR
Intervention: Individual doses of cilostazol or clopidogrel
Number of subjects: 10
Study: 16216721

Group type: EXPERIMENTAL
Intervention: Virgin argan oil (VAO) 25 ml/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extra virgin olive oil (EVO) 25 ml/day
Number of subjects: 60
Study: 12670060

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day for 28 days, then 10 mg/day thereafter
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 10078583

Group type: EXPERIMENTAL
Intervention: In vitro fertilization
Number of subjects: 28

Group type: COMPARATOR
Intervention: Ovulation induction
Number of subjects: 28
Study: 7554703

Group type: EXPERIMENTAL
Intervention: Physostigmine (2 to 12 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sustained low-dose steady-state intravenous infusion of physostigmine (0.5 to 25 mg/day)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single high-dose physostigmine (1 to 1.5 mg for 45 to 60 minutes)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single high-dose physostigmine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 9
Study: 1981022

Group type: EXPERIMENTAL
Intervention: Ketanserin 20 mg twice daily
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily
Number of subjects: 142

Group type: COMPARATOR
Intervention: Bendrofluazide 5 mg each morning plus placebo at night
Number of subjects: 142
Study: 7265942

Group type: EXPERIMENTAL
Intervention: Training on relating to objects schemes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training on means-end schemes
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Training on both means-end and relating to objects
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 32
Study: 30606197

Group type: EXPERIMENTAL
Intervention: eHealth intervention (webpage with monthly video clips and baby food recipes)
Number of subjects: 718

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 718
Study: 27720706

Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 46

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 46
Study: 26386540

Group type: EXPERIMENTAL
Intervention: VGX-3100 (6 mg, intramuscularly at 0, 4, and 12 weeks)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo (1 mL, intramuscularly at 0, 4, and 12 weeks)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: VGX-3100
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 23714362

Group type: EXPERIMENTAL
Intervention: Smartphone application intervention with a goal of 10,000 steps per day and an exercise promotion leaflet
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group encouraged to walk an additional 30 minutes per day (equivalent to 10,000 steps) with an exercise promotion leaflet
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Smartphone application intervention
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 22155910

Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Liquid formulations
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GG genotype
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 GT genotype
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: FDC tablet (GPO-VIR Z30) in children with CYP2B 516 TT genotype
Number of subjects: 42
Study: 19762048

Group type: EXPERIMENTAL
Intervention: TachoSil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard technique only
Number of subjects: 60
Study: 17902128

Group type: EXPERIMENTAL
Intervention: HCV-positive patients
Number of subjects: 177

Group type: COMPARATOR
Intervention: HCV-negative patients
Number of subjects: 177
Study: 15657502

Group type: EXPERIMENTAL
Intervention: Thallium-201 (201Tl) injection of 111-130 MBq at peak exercise and a second injection of 18.5-37 MBq of 201Tl 15 min before rest images.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Visual assessment of perfusion images.
Number of subjects: 46
Study: 11847938

Group type: EXPERIMENTAL
Intervention: brasofensine 0.5 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: brasofensine 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: brasofensine 2 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: brasofensine 4 mg
Number of subjects: 8
Study: 11243058

Group type: EXPERIMENTAL
Intervention: Ready to eat (RTE) food containing 2g of Red Palm Oil (RPO)
Number of subjects: 0
Study: 7476342

Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg orally, 120 minutes before GHRH injection
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (2 tablets orally)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Acipimox 500 mg orally
Number of subjects: 13
Study: 2277129

Group type: EXPERIMENTAL
Intervention: FS 205-397 (250 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: FS 205-397 (500 mg)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 380335

Group type: COMPARATOR
Intervention: Extended field radiotherapy alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combined modality treatment (extended field radiotherapy followed by six cycles of MOPP chemotherapy)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Combined modality therapy
Number of subjects: 87
Study: 31605877

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Recent ex-smokers
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Long-term ex-smokers
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Never smokers
Number of subjects: 1002

Group type: EXPERIMENTAL
Intervention: Current and recent ex-smokers
Number of subjects: 1002
Study: 29183357

Group type: EXPERIMENTAL
Intervention: Brief and extensive automated telephony interventions targeting problematic alcohol use
Number of subjects: 248

Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 248
Study: 25917942

Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 237
Study: 22986417

Group type: EXPERIMENTAL
Intervention: GIK solution (0.3 ml kg(‐1) h(‐2) containing potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 66
Study: 21819251

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Oral diabetes medications
Number of subjects: 2163

Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 2163

Group type: COMPARATOR
Intervention: Control group (no T2DM)
Number of subjects: 2163
Study: 18515451

Group type: EXPERIMENTAL
Intervention: Lithium carbonate 500 mg b.d. for 7 days
Number of subjects: 20
Study: 17072963

Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ) 200 mg taken three times per day (TID) for five days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Quinacrine (QC) 2 mg/kg bodyweight TID for five days
Number of subjects: 122

Group type: COMPARATOR
Intervention: Quinacrine (QC)
Number of subjects: 122
Study: 14555565

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg bid using a spacer device
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 751

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 10743449

Group type: EXPERIMENTAL
Intervention: Atropine 40 micrograms kg‐1 orally 1 h before operation (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: No premedication (group B)
Number of subjects: 120
Study: 8883676

Group type: EXPERIMENTAL
Intervention: Manual muscle test for supraspinatus muscle at 90 degrees of scapular elevation and +45 degrees of external rotation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Manual muscle test for infraspinatus muscle at 0 degree of scapular elevation and -45 degrees of internal rotation
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Gerber push-off test for subscapularis muscle
Number of subjects: 11
Study: 1328941

Group type: EXPERIMENTAL
Intervention: Desferrioxamine 30 mg/kg body-weight (30-min infusion)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Desferrioxamine doses of 5, 10, and 20 mg/kg body-weight
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Weekly doses of 5-10 mg/kg of desferrioxamine
Number of subjects: 25
Study: 3899671

Group type: EXPERIMENTAL
Intervention: Labetalol (50 mg hydrochlorothiazide and labetalol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prazosin (50 mg hydrochlorothiazide, 200 mg atenolol and prazosin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31450969

Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 45

Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 45
Study: 29105204

Group type: EXPERIMENTAL
Intervention: Food images
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cognitive eating disorder symptoms and binge eating
Number of subjects: 87
Study: 26460893

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Health Enhancement Program (HEP)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: MBSR and HEP
Number of subjects: 130
Study: 24823888

Group type: EXPERIMENTAL
Intervention: Self-paced, online educational course on complex nursing care of hospitalized patients on basal-bolus insulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 22982903

Group type: EXPERIMENTAL
Intervention: Nicotinic acid 500 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sevelamer 1600 mg
Number of subjects: 40
Study: 20473577

Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triacylglycerols (MLCT) 25-30 g/day
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT) 25-30 g/day
Number of subjects: 101
Study: 18675742

Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 46

Group type: COMPARATOR
Intervention: Vehicle patch
Number of subjects: 46
Study: 16786754

Group type: EXPERIMENTAL
Intervention: Short-term low dose glucocorticosteroids (GCS), dosage and duration not specified
Number of subjects: 0
Study: 14560861

Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 79

Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg
Number of subjects: 79
Study: 10469771

Group type: EXPERIMENTAL
Intervention: DHA supplemented formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DHA plus arachidonic acid supplemented formula
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo (no LCPUFA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Breastfed infants (control group)
Number of subjects: 0
Study: 8915561

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Phenelzine 45-90 mg/day
Number of subjects: 42
Study: 1910998

Group type: EXPERIMENTAL
Intervention: metrizamide
Number of subjects: 38

Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 38
Study: 6349537

Group type: EXPERIMENTAL
Intervention: Levamisole with Tegafur
Number of subjects: 0

Group type: COMPARATOR
Intervention: Levamisole with 5-Fluorouracil
Number of subjects: 0